2004
Induction and Concurrent Chemotherapy With High-Dose Thoracic Conformal Radiation Therapy in Unresectable Stage IIIA and IIIB Non–Small-Cell Lung Cancer: A Dose-Escalation Phase I Trial
Socinski MA, Morris DE, Halle JS, Moore DT, Hensing TA, Limentani SA, Fraser R, Tynan M, Mears A, Rivera MP, Detterbeck FC, Rosenman JG. Induction and Concurrent Chemotherapy With High-Dose Thoracic Conformal Radiation Therapy in Unresectable Stage IIIA and IIIB Non–Small-Cell Lung Cancer: A Dose-Escalation Phase I Trial. Journal Of Clinical Oncology 2004, 22: 4341-4350. PMID: 15514375, DOI: 10.1200/jco.2004.03.022.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsArea Under CurveCamptothecinCarboplatinCarcinoma, Non-Small-Cell LungCombined Modality TherapyFemaleHumansIrinotecanLung NeoplasmsMaleMiddle AgedNeoplasm StagingPaclitaxelRadiotherapy, ConformalRemission InductionSurvival AnalysisTreatment OutcomeConceptsStage III NSCLC patientsCell lung cancerClinical target volumeConcurrent chemotherapyConformal radiation therapyNSCLC patientsPerformance statusLung cancerRadiation therapyDose-escalation phase I trialTarget volumeConventional radiotherapy dosesUnresectable stage IIIAGood performance statusLocal control rateMaximum-tolerated doseDose-limiting toxicityPhase I trialMedian survival timeOverall response rateInitial clinical target volumeInduction chemotherapyFatal hemoptysisLate toxicityStage IIIA
2003
Gemcitabine-Based Combinations as Preoperative Therapy in Resectable Non–Small-Cell Lung Cancer
Socinski MA, Rivera MP, Detterbeck FC. Gemcitabine-Based Combinations as Preoperative Therapy in Resectable Non–Small-Cell Lung Cancer. Clinical Lung Cancer 2003, 4: s50-s55. PMID: 14720337, DOI: 10.3816/clc.2003.s.004.Peer-Reviewed Original ResearchGemcitabine-containing regimensPhase III trialsStage III NSCLCComplete surgical resectionPreoperative therapyIII trialsSurgical resectionInduction therapyLung cancerResectable non-small cell lung cancerNon-small cell lung cancerDominant recurrence patternGemcitabine-based combinationsSystemic micrometastatic diseaseCisplatin/gemcitabinePhase II trialMajority of patientsMinority of patientsCell lung cancerOverall response rateStandard of careAdjuvant chemotherapyAdvanced NSCLCII trialStage IB